Background: Despite marijuana is the most frequent drug use worldwide, there is no prospective clinical data of its implication in acute coronary syndromes (ACS). The aim of this study was to evaluate the prevalence of marijuana smokers in young people admitted to intensive unit care for ACS.
Material and Methods:
From September 2010 to Mars 2011, we prospectively included all patients below 50 years old admitted for ACS at the University Hospital of Toulouse, France and assessed their use of Marijuana by medical questioning and systematic urinary assay. Patients were divided into 2 groups (marijuana smokers and no marijuana smokers) according to the presence of marijuana in urines. Parametric and non-parametric tests were used for groups comparison.
Results: 63 patients were included. Mean age was 42±7 years old and 52 (82.5%) patients were male. In this cohort, 23.8% (15) were recognized as marijuana smokers (MS). There was no difference in classical cardiovascular risk factors, age and gender between the two groups. Interestingly, MS present significative more non ST elevation myocardial infarction than non MS patients (67% vs 29.2%; p=0.009). There was no difference in the coronary status but a high frequency of multivessel coronary disease (respectively 46.6% and 45.8%, p=0.95) in the two groups. There was no death in MS group whereas two in the non MS group. No difference was observed in left ejection fraction at hospital discharge (55% vs 52%, p=0.291). Marijuana addiction is characterized by an 86.7% use in the 24 hours preceding the ACS and 73.3% in the last three hours.
Conclusion:
Marijuana use is frequent, especially in the few hours preceding the event, and probably underdiagnosed in ACS of people below 50 years old. Clinical presentation of ACS is different in this group with less ST elevation suggesting a more complex coronary artery disease. Multicentric study should be achieved to assess epidemiology and pathophysiolgical role of marijuana use in ACS. Methods: Using a web-based case collection and reporting system, 123 patients with definite EST on dual antiplatelet therapy were matched 2:1 according to age and gender with 246 controls. All patients were genotyped for 23 genetic variants involved in clopidogrel metabolism (CYP2C19, CYP2C9, CYP2B6, CYP3A5, POR, ABCB1, PON1), platelet receptor function (P2Y12, ITGB3), and the coagulation and fibrinolytic system (MTHFR, Factor V, Fibrinogen, Prothrombin, PAI1 and VKORC1). 
In addition to established clinical and angiographic factors, three genes involved in clopidogrel metabolism and platelet receptor function (CYP2C19, ABCB1, ITGB3) were significantly significantly improved the ability to predict early ST. PPI use and clopidogrel dose were both independently correlated with the risk of early ST, suggesting that the final amount of active metabolite generated is a major factor of prevention. 
